Latest VIVUS Inc. Stories

MOUNTAIN VIEW, Calif., June 30, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction (ED). The NDA submission follows the successful completion of an extensive phase 3 program for avanafil, which included over 1,350 patients, where avanafil was shown to be well tolerated and effective...

MOUNTAIN VIEW, Calif., June 27, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple posters were presented at the American Diabetes Association (ADA) meeting on June 26th and 27th, 2011, in San Diego, CA. The ADA Scientific Sessions is the world's largest and most prestigious diabetes meeting. Top-line results from the CONQUER and SEQUEL studies have been previously reported, but the ADA presentations represent the first time detailed glycemic results have been...

MOUNTAIN VIEW, Calif., June 22, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts have been accepted for presentation at the upcoming American Diabetes Association (ADA) meeting to be held June 24th to June 28th, 2011, at the San Diego Convention Center, San Diego, CA. Timothy Garvey, MD, Professor of Medicine and Chair of the Department of Nutrition Sciences at UAB, will present his findings on the impact of QNEXA treatment on metabolic syndrome....

MOUNTAIN VIEW, Calif., June 17, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that the positive results from REVIVE-RP (TA-303), a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C. The meeting is jointly sponsored by the International Society for Sexual Medicine (ISSM)...

MOUNTAIN VIEW, Calif., June 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will participate in two investment conferences during the month of June. The conference presentation schedule is as follows: Bank of America Merrill Lynch Specialty Pharmaceuticals One-on- One Conference June 16, 2011 Presenter: Dr. Barbara Troupin, senior director, medical affairs Boston Harbor Hotel, Boston, MA 2011 Wells Fargo Securities...

MOUNTAIN VIEW, Calif., May 31, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the European Congress on Obesity (ECO) in Istanbul, Turkey. ECO is the official obesity congress of The European Association for the Study of Obesity (EASO). ECO is regularly attended by more than 2500 participants from over 75 countries and is considered to be the most important annual scientific event on obesity in Europe. Highlights...

MOUNTAIN VIEW, Calif., May 25, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in patients following a radical prostatectomy. The study (REVIVE-RP, TA-303) met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements...

MOUNTAIN VIEW, Calif., May 20, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the upcoming European Congress on Obesity meeting to be held May 25 to May 28, 2011, at the ICEC Lutfi Kirdar Convention & Exhibition Center in Istanbul, Turkey. The details of the presentations are as follows: Oral presentation: Friday, May 27 - Novel Drugs Session, Presentation time 17:15-17:30 (local time)...

MOUNTAIN VIEW, Calif., May 17, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C. Laurence Belkoff, DO, FACOS, Chairman of the Department of Specialty Surgeries and the Division of...

MOUNTAIN VIEW, Calif., May 13, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that data on avanafil, its investigational drug candidate, will be featured in a late breaking oral presentation at the American Urological Association (AUA) 2011 Annual Meeting, being held May 14-19, 2011 in Washington, D.C. Following are details about the presentation: The oral presentation will be given at the Walter E. Washington Convention Center in Washington, D.C., on Tuesday, May 17, 2011,...